<DOC>
	<DOCNO>NCT01506596</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety single agent pazopanib subject unresectable metastatic liposarcoma .</brief_summary>
	<brief_title>Study Pazopanib Treatment Surgically Unresectable Metastatic Liposarcoma</brief_title>
	<detailed_description>This Phase II , multicenter , prospective , open label , single arm study . The primary endpoint study progression-free rate define Response Evaluation Criteria Solid Tumors ( RECIST ) guideline version 1.1 week 12 start treatment . The secondary endpoint include overall progression-free survival ( PFS ) , response rate ( RR ) , duration response , overall survival ( OS ) , toxicity assessment report adverse event .</detailed_description>
	<mesh_term>Liposarcoma</mesh_term>
	<criteria>Written inform consent . Age &gt; = 18 year . Histologically cytologically confirm high intermediategrade liposarcoma ( allow subtypes include liposarcoma dedifferentiate , myxoid/round cell , pleomorphic , mixedtype , otherwise specify ) . Surgically unresectable metastatic disease . Any number prior treatment treatment regimen , include treatment naive subject . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Measurable evaluable ( nonmeasurable ) disease per RECIST guideline version 1.1 . Subjects must document disease progression within past 6 month . Adequate organ system function determine within 14 day prior first dose study treatment . Left ventricular ejection fraction ( LVEF ) &gt; 50 % institutional LLN within 28 day prior first dose study treatment . Females must either nonchild bear potential negative pregnancy test within 7 day prior first dose study treatment . Well differentiated liposarcoma . Prior treatment tyrosine kinase inhibitor ( TKIs ) vascular endothelial growth factor ( VEGF ) inhibitor . Prior malignancy ( Note : subject another malignancy diseasefree 3 year , subject history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma eligible ) . History clinical evidence central nervous system metastasis leptomeningeal carcinomatosis , unless previously treat , asymptomatic , steroids antiseizure medication 6 month prior first dose study drug Clinically significant gastrointestinal ( GI ) abnormality may increase risk GI bleeding . Clinically significant GI abnormality may affect absorption investigational product . Presence uncontrolled infection . Corrected QT interval &gt; 480 msec use Bazett 's formula . History certain cardiovascular condition within past 6 month . Poorly control hypertension [ define systolic blood pressure &gt; = 140 mmHg diastolic blood pressure &gt; = 90 mmHg ] . History cerebrovascular accident include transient ischemic attack , pulmonary embolism , untreated deep vein thrombosis within past 6 month . Prior major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer . Evidence active bleeding bleed diathesis . Known endobronchial lesion and/or lesion infiltrate major pulmonary vessel increase risk pulmonary hemorrhage . Hemoptysis excess 2.5 mL within 8 week first dose study drug . Any serious and/or unstable preexist medical , psychiatric , condition could interfere subject 's safety , provision inform consent , compliance study procedure . Unable unwilling discontinue use prohibit medication least 14 day five halflives drug , whichever longer , prior first dose study drug duration study treatment . Radiation therapy , minor surgery , tumor embolization , chemotherapy , immunotherapy , biologic therapy , investigational therapy , hormonal therapy within 14 day five halflives drug ( whichever longer ) prior first dose study drug . Administration nononcologic investigational drug within 30 day five halflives ( whichever longer ) prior receive first dose study drug . Any ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity , except alopecia . Known immediate delay hypersensitivity reaction idiosyncrasy drug chemically realted pazopanib excipients contraindicate participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Liposarcoma</keyword>
</DOC>